Ann Nucl Med 2008, 22:83–86.PubMedCrossRef 16. Khan MA, Combs CS, Brunt EM, Lowe VJ, Wolverson MK, Solomon H, Collins BT, Di Bisceglie AM: Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000, 32:792–797.PubMedCrossRef 17. Miyakubo M, Oriuchi N, Tsushima Y, Higuchi T, Koyama K, Arai K, Paudyal B, Iida Y, Hanaoka H, Ishikita T, Nakasone Y, Negishi A, Mogi K, Endo K: Diagnosis of maxillofacial tumor
with L-3-[18F]-fluoro-alpha-methyltyrosine (FMT) PET: a comparative study with FDG-PET. Ann Nucl Med 2007, 21:129–135.PubMedCrossRef 18. MK-8931 molecular weight Baserga R: Growth regulation of the PCNA gene. J Cell Sci 1991, 98:433–436.PubMed 19. Hong SS, Lee H, Kim KW: HIF-1alpha: a valid therapeutic target for tumor therapy. Cancer Res Treat 2004, 36:343–353.PubMedCrossRef 20. Izuishi K, Yamamoto Y, Sano T, Takebayashi R, Nishiyama Y, Mori H, Masaki T, Morishita A, Suzuki Y: Molecular mechanism underlying the detection of colorectal cancer by 18F-2-fluoro-2-deoxy-D: -glucose positron emission tomography. J Gastrointest
Surg 2012, 16:394–400.PubMedCrossRef 21. 4SC-202 Kameyama R, Yamamoto Y, Izuishi K, Sano T, Nishiyama Y: Correlation of 18F-FLT uptake with equilibrative nucleoside transporter-1 and thymidine kinase-1 expressions in gastrointestinal cancer. Nucl Med Commun 2011, 32:460–465.PubMedCrossRef 22. Kuang Y, Schomisch SJ, Chandramouli V, Lee Z: Hexokinase and glucose-6-phosphatase activity in woodchuck model of hepatitis virus-induced hepatocellular carcinoma. Comp Biochem Physiol C Toxicol Pharmacol. 2006, 143:225–231.PubMedCrossRef 23. Di Fabio F, Pinto C, Rojas Llimpe FL, Fanti S, Castellucci P, Longobardi C, Mutri V, Funaioli C, Sperandi F, Giaquinta S, Martoni AA: The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric BCKDHA adenocarcinoma treated with chemotherapy plus cetuximab. Gastric Cancer 2007, 10:221–227.PubMedCrossRef 24. Heudel P, Cimarelli S, Montella A, Bouteille C, Mognetti
T: Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors. Int J Clin Oncol 2010, 15:588–593.PubMedCrossRef 25. Izuishi K, Yamamoto Y, Sano T, Takebayashi R, Masaki T, Suzuki Y: Impact of 18-fluorodeoxyglucose positron emission tomography on the management of pancreatic cancer. J Gastrointest Surg 2010, 14:1151–1158.PubMedCrossRef 26. Usuda K, Sagawa M, Aikawa H, Ueno M, Tanaka M, Machida Y, Zhao XT, Ueda Y, Higashi K, Sakuma T: Correlation selleck between glucose transporter-1 expression and 18F-fluoro-2-deoxyglucose uptake on positron emission tomography in lung cancer. Gen Thorac Cardiovasc Surg 2010, 58:405–410.PubMedCrossRef 27.